• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Rabbit anti-Human DYNC2LI1 Polyclonal Antibody

The antibody against DYNC2LI1 was raised in rabbit using the Recombinant Human Cytoplasmic dynein 2 light intermediate chain 1 protein (1-352AA) as the immunogen. This antibody exists as a non-conjugated isotype IgG, Antigen affinity purified. This antibody has been validated on ELISA, WB, IHC.

ADC-16718A

The antibody against DYNC2LI1 was raised in rabbit using the Recombinant Human Cytoplasmic dynein 2 light intermediate chain 1 protein (1-352AA) as the immunogen. This antibody exists as a non-conjugated isotype IgG, Antigen affinity purified. This antibody has been validated on ELISA, WB, IHC.

$299.00

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ADC-16718A ClonalityPolyclonal
Host SpeciesRabbitTarget NameDYNC2LI1
Target SynonymsCGI-60 antibody; Cytoplasmic dynein 2 light intermediate chain 1 antibody; D2LIC antibody; DC2L1_HUMAN antibody; DYNC2LI1 antibody; Dynein 2 light intermediate chain antibody; Dynein, cytoplasmic 2, light intermediate chain 1 antibody; LIC3 antibodyFormLiquid
Species ReactivityHuman, MouseIsotypeIgG
Storage Buffer50% Glycerol, PBS with 0.02% sodium azide, pH7.3.Purification MethodAntigen affinity purified
ConjugateNon-conjugatedApplicationELISA, IHC, WB
StorageUpon receipt

Immunogen Information


Immunogen DescriptionRecombinant Human Cytoplasmic dynein 2 light intermediate chain 1 protein (1-352AA)Target SpeciesHuman
Immunogen SequenceComplete sequences for the immunogen, target protein, and peptides are available upon request.Uniprot IDQ8TCX1
Background Information
  • Uniprot Id

    Q8TCX1

  • Target Species

    Human

  • Target Name

    DYNC2LI1

  • Target Full Name

    Cytoplasmic dynein 2 light intermediate chain 1

  • Target Function

    Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 2 complex (dynein-2 complex), a motor protein complex that drives the movement of cargos along microtubules within cilia and flagella in concert with the intraflagellar transport (IFT) system, facilitating the assembly of these organelles. Involved in the regulation of ciliary length.

  • Target Involvement

    Short-rib thoracic dysplasia 15 with polydactyly (SRTD15)

  • Target Subcellular Location

    Golgi apparatus. Cytoplasm. Cell projection, cilium. Cytoplasm, cytoskeleton, cilium basal body. Cytoplasm, cytoskeleton, cilium axoneme. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.

  • Target Protein Families

    Dynein light intermediate chain family

  • Target Tissue Specificity

    Expressed in bone, brain, kidney, and cartilage. Lower expression in heart, liver, lung, placenta and thymus.

  • Target Research Area

    Signal Transduction

  • Target Synonyms

    CGI-60; Cytoplasmic dynein 2 light intermediate chain 1; D2LIC; DC2L1_HUMAN; DYNC2LI1; Dynein 2 light intermediate chain; Dynein, cytoplasmic 2, light intermediate chain 1; LIC3

  • Target Background

    This gene encodes a protein that is a component of the dynein-2 microtubule motor protein complex that plays a role in the retrograde transport of cargo in primary cilia via the intraflagellar transport system. This gene is ubiquitously expressed and its protein, which localizes to the axoneme and Golgi apparatus, interacts directly with the cytoplasmic dynein 2 heavy chain 1 protein to form part of the multi-protein dynein-2 complex. Mutations in this gene produce defects in the dynein-2 complex which result in several types of ciliopathy including short-rib thoracic dysplasia 15 with polydactyly (SRTD15). Alternative splicing results in multiple transcript variants encoding distinct isoforms.

Inquire Rabbit anti-Human DYNC2LI1 Polyclonal Antibody Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification